LT3056B - An antivirally active pharmaceutical oil-in-water emulsion containing 9-£(2-hydroxy-ethoxy)methyl|guanine (acyclovir) or a salt or ester thereof - Google Patents

An antivirally active pharmaceutical oil-in-water emulsion containing 9-£(2-hydroxy-ethoxy)methyl|guanine (acyclovir) or a salt or ester thereof Download PDF

Info

Publication number: LT3056B
Authority: LT; Lithuania
Prior art keywords: weight; acyclovir; water; cream; ester
Prior art date: 1992-09-09

Application number

LTIP959A

Other languages

English (en)

Lithuanian (lt)

Inventor

Knud Erik Gebhard-Hansen

Soeren Bols Pedersen

Karen Bjoernsdottir

Bodil Gyllembourg Lissau

Boerge Ingvar Frisch Alhede

Original Assignee

Gea Farmaceutisk Fabrik As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-09

Filing date

1993-09-09

Publication date

1994-10-25

1993-09-09 Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As

1994-05-15 Publication of LTIP959A publication Critical patent/LTIP959A/xx

1994-10-25 Publication of LT3056B publication Critical patent/LT3056B/lt

Links

MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims abstract description 71
229960004150 aciclovir Drugs 0.000 title claims abstract description 63
150000003839 salts Chemical class 0.000 title claims abstract description 14
150000002148 esters Chemical class 0.000 title claims abstract description 13
239000007764 o/w emulsion Substances 0.000 title claims abstract description 8
-1 2-hydroxy-ethoxy Chemical group 0.000 title claims description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title claims description 4
IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
239000006071 cream Substances 0.000 claims abstract description 81
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 71
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
239000000839 emulsion Substances 0.000 claims abstract description 21
229940074076 glycerol formal Drugs 0.000 claims abstract description 21
239000012071 phase Substances 0.000 claims abstract description 11
239000004480 active ingredient Substances 0.000 claims abstract description 9
150000005846 sugar alcohols Polymers 0.000 claims abstract description 8
239000008346 aqueous phase Substances 0.000 claims abstract description 6
239000003960 organic solvent Substances 0.000 claims abstract description 6
239000005662 Paraffin oil Substances 0.000 claims abstract description 4
235000021355 Stearic acid Nutrition 0.000 claims abstract description 4
229940057995 liquid paraffin Drugs 0.000 claims abstract description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 4
239000008117 stearic acid Substances 0.000 claims abstract description 4
239000003871 white petrolatum Substances 0.000 claims abstract description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 56
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 7
230000000840 anti-viral effect Effects 0.000 claims description 3
239000000203 mixture Substances 0.000 abstract description 15
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 abstract 2
239000000470 constituent Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 abstract 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 39
206010015150 Erythema Diseases 0.000 description 15
230000035515 penetration Effects 0.000 description 15
238000012360 testing method Methods 0.000 description 15
231100000321 erythema Toxicity 0.000 description 14
238000011282 treatment Methods 0.000 description 13
230000000694 effects Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
239000012530 fluid Substances 0.000 description 10
229940107931 zovirax Drugs 0.000 description 10
206010052428 Wound Diseases 0.000 description 9
208000027418 Wounds and injury Diseases 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
239000000902 placebo Substances 0.000 description 5
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
206010040880 Skin irritation Diseases 0.000 description 4
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
231100000475 skin irritation Toxicity 0.000 description 4
230000036556 skin irritation Effects 0.000 description 4
241000700198 Cavia Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
231100000223 dermal penetration Toxicity 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
238000000491 multivariate analysis Methods 0.000 description 2
229960003742 phenol Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
241001574715 Eremas Species 0.000 description 1
206010019972 Herpes viral infections Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
229950009789 cetomacrogol 1000 Drugs 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000010985 leather Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
239000008213 purified water Substances 0.000 description 1
231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
239000003860 topical agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LTIP959A 1992-09-09 1993-09-09 An antivirally active pharmaceutical oil-in-water emulsion containing 9-£(2-hydroxy-ethoxy)methyl|guanine (acyclovir) or a salt or ester thereof LT3056B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK111392A DK169121B1 (da)	1992-09-09	1992-09-09	Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf

Publications (2)

Publication Number	Publication Date
LTIP959A LTIP959A (en)	1994-05-15
LT3056B true LT3056B (en)	1994-10-25

Family

ID=8101156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTIP959A LT3056B (en)	1992-09-09	1993-09-09	An antivirally active pharmaceutical oil-in-water emulsion containing 9-£(2-hydroxy-ethoxy)methyl\|guanine (acyclovir) or a salt or ester thereof

Country Status (27)

Country	Link
EP (1)	EP0662819B1 (fr)
JP (1)	JPH08501089A (fr)
AT (1)	ATE137113T1 (fr)
AU (1)	AU4945393A (fr)
BG (1)	BG62032B1 (fr)
BR (1)	BR9307024A (fr)
CA (1)	CA2142493A1 (fr)
CZ (1)	CZ284007B6 (fr)
DE (1)	DE69302396T2 (fr)
DK (1)	DK169121B1 (fr)
EE (1)	EE03088B1 (fr)
ES (1)	ES2086235T3 (fr)
FI (1)	FI112777B (fr)
GR (1)	GR3019984T3 (fr)
HR (1)	HRP931160B1 (fr)
HU (1)	HUT72606A (fr)
LT (1)	LT3056B (fr)
LV (1)	LV10912B (fr)
NO (1)	NO308234B1 (fr)
PL (1)	PL172663B1 (fr)
RO (1)	RO113306B1 (fr)
RU (1)	RU2128503C1 (fr)
SI (1)	SI9300469A (fr)
SK (1)	SK280119B6 (fr)
UA (1)	UA41897C2 (fr)
WO (1)	WO1994005258A1 (fr)
ZA (1)	ZA936661B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4416674C2 (de) *	1994-05-11	1997-01-30	Rentschler Arzneimittel	Topische Zubereitung enthaltend Aciclovir
ZA96525B (en) *	1995-02-06	1996-08-06	Astra Ab	Novel pharmaceutical compositions
US6440980B1 (en) *	1996-09-17	2002-08-27	Avanir Pharmaceuticals	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
FR2753626B1 (fr) *	1996-09-20	1998-11-06	Centre International De Rech Dermatologiques Galderma Cird Galderma	Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
AU2004202929B2 (en) *	1999-09-22	2006-11-23	B. Ron Johnson	Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
WO2005067941A1 (fr) *	2004-01-08	2005-07-28	Universidad De Concepcion	Formulation topique d’aciclovir
US9050365B2 (en) *	2004-04-19	2015-06-09	Strategic Science & Technologies, Llc	Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20050257718A1 (en) *	2004-05-22	2005-11-24	Engelhard Corporation	Natural Pearl in Butylene Glycol
WO2007121318A2 (fr) *	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Préparations destinées à l'administration d'insuline
WO2008006085A2 (fr) *	2006-07-07	2008-01-10	University Of Washington	Compositions et procédés pour prédire des inhibiteurs de cibles protéiques
US11684624B2 (en)	2009-06-24	2023-06-27	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
US12138268B2 (en)	2009-06-24	2024-11-12	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
EP3045171A1 (fr)	2009-06-24	2016-07-20	Strategic Science & Technologies, LLC	Composition topique
CN105920603B (zh)	2010-12-29	2022-02-11	战略科学与技术有限责任公司	勃起功能障碍和其它适应症的治疗
US9463180B2 (en)	2013-03-14	2016-10-11	Quadex Pharmaceuticals, Llc	Treatment of molluscum contagiosum
US9125911B2 (en)	2013-03-14	2015-09-08	Quadex Pharmaceuticals, Llc	Combined systemic and topical treatment of disordered tissues
US9549930B2 (en)	2013-03-14	2017-01-24	Quadex Pharmaceuticals, Llc	Combined systemic and topical treatment of disordered and/or prodromal stage tissue
FR3023718B1 (fr) *	2014-07-16	2018-10-12	Pierre Fabre Medicament	Compositions pharmaceutique et/ou cosmetique decontaminees par haute pression
GB201819418D0 (en)	2018-11-29	2019-01-16	Daniel Calladine Ltd	Anti-viral compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523865A (en)	1974-09-02	1978-09-06	Wellcome Found	Purine compunds and salts thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2080106B (en) *	1980-07-18	1984-03-07	Weelcome Foundation Ltd	Acyclovin preparations

1992
- 1992-09-09 DK DK111392A patent/DK169121B1/da not_active IP Right Cessation
1993
- 1993-09-07 HR HR1113/92A patent/HRP931160B1/xx not_active IP Right Cessation
- 1993-09-09 UA UA95038210A patent/UA41897C2/uk unknown
- 1993-09-09 AU AU49453/93A patent/AU4945393A/en not_active Abandoned
- 1993-09-09 AT AT93919042T patent/ATE137113T1/de not_active IP Right Cessation
- 1993-09-09 SK SK291-95A patent/SK280119B6/sk unknown
- 1993-09-09 CZ CZ95599A patent/CZ284007B6/cs unknown
- 1993-09-09 SI SI9300469A patent/SI9300469A/sl unknown
- 1993-09-09 ES ES93919042T patent/ES2086235T3/es not_active Expired - Lifetime
- 1993-09-09 DE DE69302396T patent/DE69302396T2/de not_active Expired - Fee Related
- 1993-09-09 LT LTIP959A patent/LT3056B/lt not_active IP Right Cessation
- 1993-09-09 HU HU9500702A patent/HUT72606A/hu unknown
- 1993-09-09 CA CA002142493A patent/CA2142493A1/fr not_active Abandoned
- 1993-09-09 RU RU95110930A patent/RU2128503C1/ru active
- 1993-09-09 PL PL93307860A patent/PL172663B1/pl unknown
- 1993-09-09 JP JP6506765A patent/JPH08501089A/ja active Pending
- 1993-09-09 EP EP93919042A patent/EP0662819B1/fr not_active Expired - Lifetime
- 1993-09-09 WO PCT/DK1993/000288 patent/WO1994005258A1/fr not_active Ceased
- 1993-09-09 RO RO95-00478A patent/RO113306B1/ro unknown
- 1993-09-09 ZA ZA936661A patent/ZA936661B/xx unknown
- 1993-09-09 BR BR9307024A patent/BR9307024A/pt not_active Application Discontinuation
1994
- 1994-08-09 EE EE9400083A patent/EE03088B1/xx unknown
1995
- 1995-03-08 NO NO950895A patent/NO308234B1/no not_active IP Right Cessation
- 1995-03-08 BG BG99484A patent/BG62032B1/bg unknown
- 1995-03-08 FI FI951086A patent/FI112777B/fi active
- 1995-04-07 LV LVP-95-90A patent/LV10912B/en unknown
1996
- 1996-05-20 GR GR960401359T patent/GR3019984T3/el unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523865A (en)	1974-09-02	1978-09-06	Wellcome Found	Purine compunds and salts thereof

Also Published As

Publication number	Publication date
SK280119B6 (sk)	1999-08-06
CZ284007B6 (cs)	1998-07-15
DK111392D0 (da)	1992-09-09
BG62032B1 (bg)	1999-01-29
FI951086A0 (fi)	1995-03-08
NO950895L (no)	1995-03-08
DK111392A (da)	1994-03-10
HRP931160B1 (en)	1999-04-30
EP0662819A1 (fr)	1995-07-19
UA41897C2 (uk)	2001-10-15
RU2128503C1 (ru)	1999-04-10
WO1994005258A1 (fr)	1994-03-17
JPH08501089A (ja)	1996-02-06
FI951086A7 (fi)	1995-03-08
EP0662819B1 (fr)	1996-04-24
LV10912A (lv)	1995-12-20
SK29195A3 (en)	1997-01-08
HUT72606A (en)	1996-05-28
NO950895D0 (no)	1995-03-08
LV10912B (en)	1996-08-20
DE69302396T2 (de)	1996-08-14
AU4945393A (en)	1994-03-29
RO113306B1 (ro)	1998-06-30
BG99484A (bg)	1995-12-29
ZA936661B (en)	1994-05-20
FI112777B (fi)	2004-01-15
EE03088B1 (et)	1998-06-15
HU9500702D0 (en)	1995-04-28
CA2142493A1 (fr)	1994-03-17
GR3019984T3 (en)	1996-08-31
ATE137113T1 (de)	1996-05-15
CZ59995A3 (en)	1995-09-13
HRP931160A2 (en)	1995-12-31
BR9307024A (pt)	1999-06-29
ES2086235T3 (es)	1996-06-16
LTIP959A (en)	1994-05-15
PL307860A1 (en)	1995-06-26
NO308234B1 (no)	2000-08-21
DE69302396D1 (de)	1996-05-30
PL172663B1 (pl)	1997-10-31
DK169121B1 (da)	1994-08-22
SI9300469A (en)	1994-03-31
RU95110930A (ru)	1997-03-27

Legal Events

Date	Code	Title	Description
2000-04-25	MM9A	Lapsed patents	Effective date: 19990909

Publication	Publication Date	Title
LT3056B (en)	1994-10-25	An antivirally active pharmaceutical oil-in-water emulsion containing 9-£(2-hydroxy-ethoxy)methyl\|guanine (acyclovir) or a salt or ester thereof
CA1228812A (fr)	1987-11-03	Fabrication de produits pharmaceutiques inedits pour usage topique
JP4603164B2 (ja)	2010-12-22	ムースの組成
AU655935B2 (en)	1995-01-19	Pharmaceutical composition of florfenicol
KR20100047840A (ko)	2010-05-10	디클로페낙의 신규한 비수용성 국소 용액 및 이를 제조하는 과정
JP3487633B2 (ja)	2004-01-19	皮膚疾患治療乳剤
US20210401989A1 (en)	2021-12-30	Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair
BG64664B1 (bg)	2005-11-30	Нимезулидни гел системи за локално приложение
WO2007133944A2 (fr)	2007-11-22	Administration topique d'acyclovir
JP2570342B2 (ja)	1997-01-08	外用液剤
JPH0383924A (ja)	1991-04-09	経皮投与用組成物
US5128135A (en)	1992-07-07	Percutaneous or trans-mucosal absorption enhancers, preparations containing the enhancers, and a method of preparing thereof
RU2182478C1 (ru)	2002-05-20	Стимулятор роста волос
JPS63270614A (ja)	1988-11-08	透明ゲル基剤
CZ256592A3 (en)	1993-03-17	Pharmaceutical composition containing bradykinin antagonists for local use in nose and eye
RU2181584C1 (ru)	2002-04-27	Стимулятор роста волос
KR100439204B1 (ko)	2004-07-07	메토트렉세이트를 유효성분으로 함유하는 경피투여용 조성물
HU230542B1 (hu)	2016-11-28	Dimetikont tartalmazó aciklovir készítmények
RU2667465C2 (ru)	2018-09-19	Фармацевтическая композиция для наружного применения, содержащая соль декскетопрофена, и способ ее получения
HK40102567A (zh)	2024-06-07	具有高吸收率的双氯芬酸局部制剂
HK40072344A (en)	2022-11-25	Topical acyclovir formulations and uses thereof
JPH0232019A (ja)	1990-02-01	外用剤
EA022317B1 (ru)	2015-12-30	Лекарственное средство, обладающее антивирусным, антибактериальным, антигрибковым, противоожоговым действием, и способ его получения
ITMI972889A1 (it)	1999-06-30	Composizioni farmaceutiche per uso topico e/o transdermale
CS269593B1 (sk)	1990-04-11	Topioký pripravok β antiflogistickým ji účinkom